Ovarian Cancer in India: Early Warning Signs to Know

• Four cardinal symptoms matter most: persistent bloating, pelvic or lower-abdominal pain, feeling full quickly, and new urinary urgency or frequency.
• The red-flag rule: if any of these is new for you, happens almost daily, and lasts more than about 12 days in a month, see a gynaecologist.
• Stage at diagnosis decides everything — around 90% 5-year survival at stage I versus 30–50% at stage III, where most Indian women are found.
• There is no national screening test for ovarian cancer, so recognising symptoms early is the single biggest thing you can control.
• Family history of breast or ovarian cancer and BRCA gene mutations raise risk sharply — but about 75% of cases happen with no family history at all.
• Pregnancy, breastfeeding and several years of the combined contraceptive pill all genuinely lower ovarian cancer risk.

Ovarian cancer is a malignant tumour that starts in an ovary — the almond-sized organ on either side of the uterus that releases an egg each month and makes oestrogen and progesterone. It is the deadliest of the gynaecological cancers, and in India it causes more deaths than any other cancer of the female reproductive organs.

There isn't just one ovarian cancer. About 90% are epithelial cancers, which begin in the surface lining of the ovary; the commonest subtype is high-grade serous carcinoma, with endometrioid, clear cell and mucinous types also in this group. Around 5–10% are germ cell tumours, which can appear in teenagers and women in their twenties. A smaller group, sex cord stromal tumours such as granulosa cell tumours, can make hormones and show up as abnormal bleeding.

The ovaries sit deep in the pelvis with plenty of room to grow before anything feels wrong. By the time a tumour presses on the bladder, bowel or stomach — or has leaked cells into the abdomen — the symptoms are still vague: a little bloating, mild pelvic ache, feeling full after a few bites. These are exactly the complaints many women have been taught to dismiss as a normal part of being a woman.

That is why knowing the early signs matters more than waiting for a dramatic warning. Early-stage ovarian cancer can often be cured. Late-stage disease is far harder to treat. The gap between those two outcomes is frequently just a few months of paying attention.

India records an estimated 30,000-plus new ovarian cancer cases and around 21,000 deaths each year, based on figures compiled from the Indian Council of Medical Research's National Cancer Registry Programme and GLOBOCAN data. Ovarian cancer is among the most common cancers in Indian women and is the leading cause of death from gynaecological cancer.

Roughly 75% of Indian women are diagnosed at stage III or IV, after the cancer has spread within or beyond the abdomen. At that point 5-year survival is around 30–50%. Caught at stage I, the same cancer carries a 5-year survival close to 90%. Stage at diagnosis is the single strongest predictor of outcome — and India's late stage distribution is the hardest part of the story.

The age peak is 50 to 70 years, but this is not only an older woman's disease. Germ cell tumours occur in girls and young women, and BRCA-related cancers often begin in the forties. A family history of early breast or ovarian cancer changes the picture significantly, as the genetics section explains.

Awareness remains low compared with breast or cervical cancer, and unlike cervical cancer screening, there is no national screening programme for the ovaries. So the whole chain of early detection depends on a woman noticing a vague symptom, taking it seriously, and reaching a gynaecologist who orders the right scan and blood test. Time is lost at every link.

• Persistent bloating. Not the after-meal kind or the once-a-month period bloating, but a sense of abdominal fullness or visible swelling that does not settle. Many women notice their clothes feeling tighter at the waist even though their weight hasn't changed. If this happens most days for more than a couple of weeks, see a gynaecologist.
• Pelvic or lower-abdominal pain. A dull ache, pressure or heaviness that is new for you, does not match your usual period pattern, and lasts for weeks. It can be mild enough to ignore at first — which is part of the trap. (For ongoing pelvic ache that isn't clearly cyclical, see chronic pelvic pain in women.)
• Feeling full quickly, or difficulty eating (early satiety). You sit down to a meal, take a few bites, and can't eat more; the food sits heavily. This is one of the most under-recognised ovarian cancer symptoms in Indian women because it is so often blamed on gastritis, indigestion or age.
• Urinary urgency or frequency. Needing to pass urine more often, more urgently or more suddenly than before, and not because you're drinking more. A growing ovarian mass presses on the bladder. Many women are first told they have a UTI; when the urine culture keeps coming back clear, ovarian causes deserve a look.
• The rule that matters: if any of these four is new for you, happens almost daily, and has lasted more than about 12 days in a single month, book a gynaecologist appointment. One day of bloating is not ovarian cancer. Three weeks of daily bloating, early fullness and urinary urgency is a signal worth investigating, even if the answer turns out to be benign.
• Two or more of the four together raise suspicion further. Most women with these symptoms will not have ovarian cancer — irritable bowel syndrome, fibroids, ovarian cysts and endometriosis all cause similar complaints — but the cost of one ultrasound is far smaller than the cost of a missed diagnosis.

Beyond the four cardinal symptoms, ovarian cancer can also bring unexplained fatigue, unintentional weight loss, persistent low back pain, new constipation that doesn't respond to the usual measures, pain during sex, and irregular vaginal bleeding — particularly any bleeding after menopause, which should always be checked.

In advanced disease the picture changes. Ascites — fluid building up in the abdomen — is a classic late sign: the belly looks swollen out of proportion to the rest of the body, and weight is lost from the limbs and face. That combination is a red flag.

Bowel obstruction can develop when tumour deposits coat the intestines and slow them down, causing vomiting, severe constipation and pain that brings a woman to the emergency department; ovarian cancer is sometimes first found on the CT scan ordered there. Late spread to the lining around the lung can cause a pleural effusion and breathlessness on minimal effort.

None of these late presentations is what we want. The entire point of the cardinal-symptom list is to reach the gynaecologist long before any of this develops.

• Family history of breast or ovarian cancer is the strongest risk factor after age. A woman with a first-degree relative (mother, sister or daughter) with ovarian cancer has roughly three times the average risk; two affected relatives or early-onset breast cancer pushes it higher.
• BRCA1 and BRCA2 gene mutations raise lifetime ovarian cancer risk to roughly 40–60% (BRCA1) and 15–25% (BRCA2), against about 1.5% in the general population. These mutations also raise breast cancer risk and explain many of the Indian families where several relatives are affected. A BRCA test in India can clarify the picture.
• Lynch syndrome (hereditary non-polyposis colorectal cancer) raises ovarian, endometrial and bowel cancer risk together; families with that cluster should be offered genetic carrier screening and counselling.
• A personal history of breast cancer raises ovarian cancer risk, partly through shared risk factors and the high BRCA overlap.
• Never having been pregnant (nulliparity) raises risk modestly, while each full-term pregnancy lowers it. Early first periods and late menopause — more lifetime ovulations — also nudge risk up.
• Postmenopausal hormone therapy, particularly oestrogen-only HRT used for several years, is linked to a small rise in risk that falls again after stopping.
• Endometriosis raises the risk of certain subtypes, especially clear cell and endometrioid carcinoma. See what endometriosis is for the bigger picture, and whether endometriosis is hereditary for the family angle.
• Obesity, PCOS and smoking (smoking mainly for the mucinous subtype) each add smaller amounts of risk.
• The central reality none of this changes: around 75% of ovarian cancers in India are sporadic, with no family history and no obvious risk factor. Being low-risk does not exempt anyone from watching for the cardinal symptoms.

• Pregnancy and breastfeeding both lower ovarian cancer risk. The leading theory is that pausing ovulation rests the ovary from the repeated wound-and-repair cycle that may seed cancer over decades. Each full-term pregnancy reduces risk by roughly 20%.
• The combined oral contraceptive pill is one of the most powerful protectors known. Five or more years of use cuts ovarian cancer risk by around 50%, and the protection lasts for decades after stopping. For women with strong family history or BRCA mutations it is often actively recommended. See birth control pills in India for how they work and how to choose one.
• Tubal ligation (tying the fallopian tubes) lowers risk by around a third, probably because most high-grade serous cancers actually begin in the fallopian tube rather than the ovary itself. See tubal ligation and sterilisation options.
• Hysterectomy lowers risk somewhat even when the ovaries are left in place, again partly through the fallopian-tube mechanism. Hysterectomy types and the decision covers this in detail.
• Risk-reducing salpingectomy (removing the fallopian tubes while keeping the ovaries) is increasingly offered to BRCA-positive women who have completed their family, or added to other pelvic surgery, since it removes the most likely site of origin without causing surgical menopause.
• Risk-reducing salpingo-oophorectomy (removing tubes and ovaries together) is the most powerful preventive surgery for BRCA carriers, usually advised around age 35–40 for BRCA1 and 40–45 for BRCA2 once childbearing is complete. It cuts ovarian cancer risk by around 80–95%.

When a woman comes to an Indian gynae OPD with persistent bloating, pelvic pain, early fullness or urinary urgency, the workup follows a fairly standard path. It starts with a pelvic examination to feel for an ovarian or pelvic mass, abdominal swelling or fluid.

The first imaging is almost always a transvaginal ultrasound (TVS). A small probe placed gently inside the vagina shows the ovaries and uterus far more clearly than an abdominal scan in adult women. The radiologist notes the size of any mass and whether it is purely fluid-filled (a simple cyst, usually benign) or has solid areas, papillary projections, internal walls or thick septations (more concerning). TVS costs roughly ₹500–2,500 at private centres and is the single most important test in this workup.

Alongside the scan, the gynaecologist usually orders the CA-125 blood test — a tumour marker that can be raised in ovarian cancer. It is most useful after menopause, where a level above 35 U/mL plus a suspicious mass is highly suggestive. Before menopause it is less specific, because it also rises with endometriosis, pelvic infection, fibroids, pregnancy and even normal periods. CA-125 costs around ₹500–2,000 at private labs such as Thyrocare, Metropolis, SRL or Apollo.

The Risk of Malignancy Index (RMI) combines the ultrasound features, the CA-125 level and menopausal status into a single number. A high RMI means the woman should be referred to a gynaecologic oncologist rather than operated on at a general centre — one of the most outcome-changing decisions in the whole pathway.

If the RMI is high or the picture is otherwise suspicious, CT or MRI of the abdomen and pelvis is done for staging, to see whether the cancer has spread to the peritoneum, lymph nodes, liver or lungs. These scans cost roughly ₹3,000–15,000 privately and less at government hospitals.

The definitive diagnosis is made at surgery — removing the mass, the affected ovary and surrounding tissue for histopathology. Unlike many cancers, needle biopsy of an ovarian mass is generally avoided because it can rupture the capsule and spill cancer cells into the abdomen, worsening the stage.

Ovarian cancer is staged using the FIGO (International Federation of Gynaecology and Obstetrics) system, from I to IV. Stage at diagnosis is by far the strongest predictor of how well treatment will work.

Stage I means the cancer is confined to one or both ovaries, with no spread. 5-year survival is around 90% — most women are cured.

Stage II means spread to other pelvic organs (fallopian tubes, uterus, bladder or rectum) but not beyond the pelvis. 5-year survival is roughly 70%.

Stage III means spread beyond the pelvis into the abdomen — the peritoneum, omentum, surface of the bowel or liver, or nearby lymph nodes. This is where most Indian women are diagnosed, with 5-year survival around 30–50% depending on how completely the surgeon can remove visible disease.

Stage IV means distant spread — to the lung, inside the liver substance, or other distant organs. 5-year survival is around 15–25%.

The number that should drive conversations about ovarian cancer in India is not the survival figure for advanced disease. It is the gap between stage I and stage III — 90% versus 30–50%. That gap is where awareness of the cardinal symptoms genuinely changes outcomes.

• Stage I (and selected stage II) is treated with surgery — total abdominal hysterectomy with removal of both tubes and ovaries (TAH-BSO), omentectomy and lymph-node sampling. For a young woman with very early stage IA who wants future fertility, a more conservative operation that keeps the uterus and one ovary is sometimes possible at specialist centres. Chemotherapy is added for higher-grade stage I and most stage II disease.
• Stage III and IV are treated with cytoreductive (debulking) surgery plus chemotherapy. The aim of debulking is to remove as much visible cancer as possible — the closer to zero residual disease, the better the survival. This is highly skilled surgery, best done at a comprehensive cancer centre by a gynaecologic oncologist.
• Standard first-line chemotherapy is carboplatin and paclitaxel, given into a vein every three weeks for six cycles. It is well established worldwide and widely available across Indian cancer centres. Common side effects include hair loss, fatigue, low blood counts and tingling in the hands and feet (peripheral neuropathy).
• PARP inhibitors — oral targeted drugs such as olaparib and niraparib — are now used as maintenance after first-line chemotherapy for BRCA-mutated cancers and, increasingly, other groups. They meaningfully extend the disease-free interval. Cost is high (often several lakhs a year), though PMJAY and manufacturer assistance programmes may help eligible patients.
• Neoadjuvant chemotherapy — chemotherapy first, surgery second — is an option for very advanced disease when a woman isn't fit for major upfront surgery: three cycles shrink the tumour, surgery removes what remains, and three more cycles follow.
• Hyperthermic intraperitoneal chemotherapy (HIPEC) bathes the abdomen with heated chemotherapy at the end of debulking surgery, and is offered to carefully selected patients with peritoneal disease at some Indian centres.
• Recurrence is common in advanced disease. Later treatments include further chemotherapy, PARP inhibitors, and emerging immunotherapy and antibody-drug conjugate options at major centres.

Genetic testing for BRCA1 and BRCA2 is one of the most powerful tools available to Indian families with a strong personal or family history of breast or ovarian cancer. A positive result does not mean cancer will happen — it means risk is much higher than average, and that several effective preventive options open up. The practical side, including BRCA testing cost in India, is worth understanding before you book.

Testing is worth considering for women with personal or family history of breast or ovarian cancer at a young age (breast under 50, ovarian at any age), several affected first-degree relatives, male breast cancer in the family, triple-negative breast cancer under 60, or a known BRCA-positive relative. Ashkenazi Jewish ancestry carries higher BRCA prevalence but is uncommon in India.

The test itself is a blood draw or saliva sample. In India, BRCA1 and BRCA2 panel testing typically costs ₹15,000–50,000 at private genetic labs such as MedGenome, Mapmygenome and Strand. Larger hereditary-cancer panels that also cover Lynch syndrome sit at the higher end. PMJAY covers genetic testing at some empanelled cancer centres for eligible patients.

Pre-test and post-test genetic counselling is the most important part of the process. A counsellor explains what positive, negative and variant-of-uncertain-significance results mean, what they imply for the woman, and what they imply for her sisters, daughters and other relatives. Testing without counselling can do real harm; testing with counselling can change a family's future.

For a BRCA-positive woman, options include high-intensity surveillance (annual CA-125, TVS and breast MRI), the combined contraceptive pill for ovarian risk reduction, and risk-reducing surgery to remove the tubes and ovaries after childbearing — typically at 35–40 for BRCA1 and 40–45 for BRCA2. Risk-reducing mastectomy is a separate decision on the breast side. None of these is mandatory; all are choices the woman makes with her care team.

• Ayushman Bharat PMJAY covers ovarian cancer surgery, chemotherapy and most diagnostic workup for eligible families up to ₹5 lakh a year, cashless at empanelled hospitals nationwide. For a complex case the limit may not cover everything, but it covers the bulk of standard care.
• Comprehensive cancer centres are where ovarian cancer should ideally be treated, because survival at stage III and IV depends heavily on the surgical team's experience. National leaders include Tata Memorial Hospital (Mumbai), the AIIMS network, CMC Vellore, JIPMER Puducherry, Kidwai Memorial Institute of Oncology (Bengaluru) and Cancer Institute (WIA) Chennai, alongside private chains such as HCG, Apollo and Fortis with dedicated gynaecologic oncology units.
• Surgery in the private sector typically runs ₹50,000–3,00,000 depending on the centre, surgeon and complexity. Public-sector and PMJAY pricing is dramatically lower.
• Chemotherapy with carboplatin and paclitaxel costs roughly ₹15,000–50,000 per cycle privately for drugs and admission, with six cycles the usual course. Government cancer hospitals provide it at very low or no cost.
• PARP inhibitors are the most expensive part — olaparib and niraparib can run to several lakhs a year. Manufacturer assistance programmes and PMJAY at some empanelled centres can substantially reduce out-of-pocket cost.
• BRCA genetic testing costs ₹15,000–50,000 at private labs, with PMJAY coverage at some empanelled centres. Even when paid for privately, it is usually a one-time test that informs decades of surveillance and prevention decisions for the whole family.

• Any of the four cardinal symptoms — bloating, pelvic or lower-abdominal pain, feeling full quickly, or new urinary urgency — that is new for you, happens almost daily, and lasts more than about 12 days in a month. Ask for a pelvic exam, a transvaginal ultrasound and, where appropriate, a CA-125.
• Two or more of those symptoms together, even if each one feels mild.
• Any vaginal bleeding after menopause — this always needs assessment.
• A visibly swelling abdomen with weight loss from the arms, legs or face.
• Persistent "IBS-like" symptoms that have started for the first time after age 50, rather than a lifelong pattern.
• A strong family history of breast, ovarian or bowel cancer — ask for a referral to genetic counselling even if you currently have no symptoms.

• Myth: a Pap smear picks up ovarian cancer. Fact: the Pap smear screens the cervix only, not the ovaries. A normal Pap is reassuring for cervical cancer but tells you nothing about the ovaries — see cervical cancer screening for what it actually covers.
• Myth: only older women get ovarian cancer. Fact: the age peak is 50 to 70, but germ cell tumours can occur in teens and twenties, and BRCA-related cancers often appear in the forties.
• Myth: no family history means no risk. Fact: around 75% of ovarian cancers are sporadic, with no family history at all. Low-risk is not no-risk, and the cardinal symptoms still apply.
• Myth: an ovarian cyst always turns into cancer. Fact: most cysts in premenopausal women are benign functional cysts that come and go with the cycle. What matters is size, solid components, age and CA-125 — see ovarian cysts and when to worry.
• Myth: persistent bloating is just irritable bowel. Fact: often it is, and IBS is far more common than ovarian cancer. But daily bloating for more than about 12 days in a month, especially with another cardinal symptom, deserves at least a TVS and CA-125 before being labelled IBS — much as new bowel symptoms after 50 warrant colorectal cancer screening.
• Myth: CA-125 is a screening test for everyone. Fact: it is not a screening test for the general population. It is used when there is a symptom or a pelvic mass under investigation. Routine CA-125 in healthy average-risk women causes more harm — false alarms, unnecessary surgery — than good.
• Myth: if I had my uterus removed I cannot get ovarian cancer. Fact: a hysterectomy that left the ovaries in place still leaves ovarian cancer possible. Risk is somewhat lower, but the cardinal symptoms still apply.

• World Health Organization — Ovarian cancer
• Indian Council of Medical Research — National Cancer Registry Programme
• GLOBOCAN / IARC Global Cancer Observatory — India fact sheet
• NHS — Ovarian cancer: symptoms, diagnosis and treatment
• American College of Obstetricians and Gynecologists (ACOG) — Ovarian Cancer
• FIGO — Ovarian, fallopian tube and peritoneal cancer staging